A randomized trial of clitoral vacuum suction versus vibratory stimulation in neurogenic female orgasmic dysfunction

Publication date: Available online 9 September 2017
Source:Archives of Physical Medicine and Rehabilitation
Author(s): Marcalee Alexander, Khurram Bashir, Craig Alexander, Lesley Marson, Raymond Rosen
ObjectiveTo examine safety and efficacy of use of a clitoral vacuum suction device (CVSD) versus vibratory stimulation (V) to treat orgasmic dysfunction in women with MS or SCI.DesignRandomized clinical trial.SettingTwo academic medical centers.ParticipantsThirty-one women including 20 with MS and 11 with SCI.InterventionA 12-week trial of the use of a CVSD versus VMain Outcome measuresFemale Sexual Function Inventory (FSFI) and Female Sexual Distress Scale (FSDS).Results23 women (18 MS; 5 SCI) completed the study including 13/16 randomized to CVSD and 10/15 randomized to V. There was a statistically significant increase in total FSFI score (p=.011), desire (p=. 009), arousal (p=.009), lubrication (p=.008), orgasm (p=.012), and satisfaction (p=.049) and a significant decrease in distress as measured by FSDS (p=.020) in subjects using the CVSD. In subjects who used V, there was a statistically significant increase in the orgasm subscale of the FSFI (p=.028). Subjects using the CVSD maintained improvements 4 weeks after treatment.ConclusionCVSD is safe and overall efficacious to treat female neurogenic sexual dysfunction related to MS and SCI. V is also safe and efficacious to female neurogenic orgasmic dysfunction; however, results were limited to the active treatment period. Due to ease of access and cost, clinicians can consider use of V for women with MS or SCI with orgasmic dysfunction. CVSD is recommended for women with multiple sexual dysfunctions or for whom V is ineffective.



http://ift.tt/2wRB0Tg